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Although the prevalence of Barrett’s esophagus (BE) is rising no data exist for racial minorities on prevalence in the
general population. Minorities have a lower prevalence than Caucasians, and yet age, smoking, abdominal obesity,
and Helicobacter pylori are all risk factors. Metabolic changes induced by adipocytokines and the apparently strong
association between obesity, central adiposity, and BE may lead to reconsideration of some aspects of the natural
history of BE. There is lack of experimental evidence on acid sensitivity and BE, which is hyposensitive compared
to esophageal reflux disease. Reactive nitrogen and oxygen species lead to impaired expression of tumor suppressor
genes, which can lead to cancer development; thus, antioxidants may be protective. Gastroesophageal reflux disease
may be considered an immune-mediated disease starting at the submucosal layer; the cytokine profile of the mucosal
immune response may explain the different outcome of gastroesophageal reflux.
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Concise summaries
• Although we do not have data from randomized
trials to definitively demonstrate what accounts
for the rising incidence of Barrett’s esophagus
(BE), there are very good epidemiological data
to support a role for rising obesity rates and de-
clining Helicobacter pylori prevalence. The issue
of why BE is less common in Asian countries re-
mains somewhat enigmatic. However, it is not
just Asia; BE is rare in the Caribbean, the Middle
East, and much of Africa and South America.
The ingestion of a high-fat diet with its asso-
ciated delayed gastric emptying, and possibly
oral and salivary carcinogens that are activated
in the region of the GE junction, may all play a
role.
• BE and esophageal adenocarcinoma are
strongly associated with obesity. Obesity
likely promotes both symptomatic and
asymptomatic gastroesophageal reflux disease
(GERD) through mechanical effects, and obese
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individuals are likely to behave in ways that also
promote GERD. In addition, adipose tissue is
metabolically active, and secreted adipokines
have been associated with the development of a
number of cancers. The rapid rise in incidence
in esophageal adenocarcinoma may be due to
synergies between these multiple mechanisms
of obesity promoting the cancer.
• The natural history of H. pylori gastritis is for the
inflammation to progress from the antrum into
the adjacent corpus. The advancing atrophic
front of corpus injury incrementally destroys
parietal cells causing further reduction in acid
secretion with the eventual development of ex-
tensive corpus atrophy. The extent and severity
of gastric atrophy, in particular corpus atrophy,
determines the patient’s risk for GERD follow-
ing H. pylori eradication.
• Indirect and direct evidence exists of acid hy-
posensitivity in patients with BE compared to
other groups of reflux patients. However, in
comparison with healthy individuals, the di-
rect evidence is sparse and results conflicting.
Not until BE patients have been compared to
healthy patients in experimental studies, where
the nature of the acid stimulus is controlled,
can it be shown if patients with BE are truly
acid hyposensitive.
• Patients with BE may have a generalized sen-
sory defect in the esophagus, independent of
nervous changes related to the metaplastic mu-
cosa. Hence, the hyposensitivity is a cardi-
nal feature that may bias the clinical evalua-
tion and monitoring of patients with BE, and
may be one of several pathogenetic factors
in BE to be studied in more detail. Depend-
ing on the true prevalence and incidence of
BE in children, BE in adults may possibly be
congenital—an abnormality of incomplete em-
bryogenesis perhaps related to the cervical inlet
patch.
• The role of individual constituents of the gas-
tric reflux in the development of BE and its as-
sociated complications still remain uncertain.
Gastric acid and pepsin have received the most
attention; however, the development of BE in
a few achlorhydric or postgastrectomy patients
suggests a possible role for the duodenal con-
tents. The duodenal contents suspected of caus-
ing esophageal mucosa injury include bile acids
and lysolecithin present in the bile secretions as
well as the pancreatic enzymes trypsin. Several
studies in humans confirm that a synergy exists
between acid and duodeno-gastro-esophageal
reflux, which may contribute to the develop-
ment of esophagitis and possibly BE.
• There is strong evidence that oxidative stress
drives neoplastic development in Barrett’s tis-
sues. Dietary antioxidant levels appear to pre-
vent neoplastic development and hence support
the concept that reactive oxygen species (ROS)
are crucial carcinogens in these patients. There
is, however, some controversy as to whether di-
etary antioxidants or antioxidant supplements
are the best source of protection. The relative
contributions of acid and bile to the generation
of these ROS, along with the pathways/enzymes
leading to these ROS require further study. DNA
damage is one of the most detrimental effects of
exposure to toxic, caustic, and harmful agents.
• One of the culprits that elicits a response by
the cell to develop defense mechanisms is the
DNA damage incurred by bile acid-associated
ROS, nitric oxide (NO), and acid-mediated in-
creases in ROS and hydrolysis. These mecha-
nisms of damage become synergistic when bile
acids are combined with acid. DNA damage be-
comes more pronounced and the cells are forced
to adapt, incur mutations, and progress through
Barrett’s to cancer.
• GERD may be considered an immune-mediated
disease starting at the submucosal layer. The cy-
tokine profile of the mucosal immune response
may explain the different outcome of gastre-
sophageal reflux, the severity of mucosal injury
and even the relapse of esophagitis. Finally, this
new concept opens the way to the development
of new treatment for patients who do not re-
spond to proton pump inhibitors (PPIs), and
to the prevention of carcinogenesis.
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1. The prevalence of BE in the general
population: what do we know?
Gary W. Falk
gary.falk@uphs.upenn.edu
The incidence of BE has increased markedly since
the 1970s.1 This increase was once felt to be due to
the increased use of diagnostic upper endoscopy
combined with the change in the definition of
BE to include shorter segments of columnar-lined
epithelium. However, data from the Netherlands2
suggest that the incidence of BE has increased from
14.3/100,000 person years in 1997 to 23.1/100,000
person years in 2002 in the general population–
independent of the number of upper endoscopies.
It is estimated that BE is found in approximately
5–15% of patients undergoing endoscopy for symp-
toms of GERD. A study of a high-risk patient
population (chronic GERD, Caucasian race, age >
50) undergoing endoscopy for symptoms of GERD
found BE in 13.2% of the subjects. The prevalence of
long segment BE (≥3 cm of intestinal metaplasia) is
approximately 5%, whereas that of short segment BE
(<3 cm of intestinal metaplasia) is approximately 6–
12% in patients undergoing endoscopy in a variety
of settings.
BE is predominantly a disease of middle-aged
white males. However, it should be kept in mind
that approximately 25% of BE patients are women
or less than 50 years of age. The prevalence of BE
increases until a plateau is reached between the sev-
enth and ninth decades. A variety of risk factors have
been identified for the presence of BE, including fre-
quent and long standing reflux episodes, smoking,
male gender, older age, and central obesity. Body
mass index itself does not appear to be a risk factor
for BE, but rather the central obesity characteristic
of male pattern obesity.
There have been two population-based studies to
address the prevalence of BE in the general popula-
tion. The first study by Ronkainen et al.3 performed
upper endoscopy in a random sample of 1,000 in-
dividuals from the adult population in two munici-
palities from Sweden. BE was found in 1.6% of these
individuals: long segment (≥2 cm) in 0.5% and
short segment (<2 cm) in 1.1%. Furthermore, only
56% of the individuals had symptoms of GERD. The
Loiano-Monghidoro study4 examined 1,033 adults
from two Italian villages that were similar in char-
acteristics to the general Italian populations. BE was
found in 1.3%; 0.2% had long segment BE, whereas
1.1% had short segment BE. Reflux symptoms were
reported by 53.8% of the Barrett’s patients. Finally,
a computer simulation, using the Surveillance Epi-
demiology and End Results (SEER) database was
recently performed5 in an effort to determine the
prevalence of BE in the United States. This study
estimated that the prevalence of BE in the general
population was 5.6%.
Taken together, the above information suggests
that: (1) BE is uncommon in the general popu-
lation (1.3–1.6%); (2) most of the patients found
in the general population have short segments;
(3) screening strategies based on reflux symptoms
alone will miss almost 50% of Barrett’s patients; and
(4) current symptom based screening concepts are
clearly problematic.
2. Can the reasons for the epidemic rate of




To address this question, we must first determine
whether the incidence of BE is indeed rising. If there
is simply greater use of upper gastrointestinal (GI)
endoscopy, there may be a detection bias that ex-
plains an increasing number of overall cases of BE
(i.e., increased prevalence, but not incidence). How-
ever, van Soest et al. provide compelling evidence
that the incidence is rising by controlling for the use
of endoscopy.1 To explain this rise then, we must
consider the various risk factors for BE and deter-
mine whether there is more exposure to these risks.
The most well-documented risks include increasing
age, male gender, Caucasian ethnicity, cigarette use,
increased body mass index (BMI), and a lack of H.
pylori infection. Because the world’s male-to-female
ratio has not changed recently, and because there
have not been significant increases in the relative
number of Caucasians, these two risks are unlikely
to explain the rising BE incidence. Let us consider
the others.
Cigarette use in the United States rose steadily
during the early to mid-1900s but has been declining
steadily since the 1970s, so on first pass, this seems
unlikely to explain the increased incidence of BE.
However, if there is a prolonged latency between
exposure to cigarettes and development of BE, this
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could still be an explanation. In this scenario, we
would expect a subsequent decline in BE incidence
over the next several decades.
Greater age is associated with BE, and the U.S.
population is indeed aging, with the so-called “baby
boomer” generation now reaching 65 years. There-
fore, this growth in the number of relatively older
people may be an explanation for the rising inci-
dence. Just as with cigarettes, however, we would
expect a decline in BE incidence over the next few
decades as the mean population age is expected to
fall.
H. pylori infection causes a chronic gastritis that
can, after many years, be associated with decreased
production of acid. Therefore, it is perhaps not sur-
prising that several studies have documented an in-
verse association between H. pylori infection and
BE.6 It appears that the more virulent strains of H.
pylori (the CagA-positive strains) may be more rele-
vant here, with one meta-analysis demonstrating an
inverse association between CagA-positive H. pylori
infection and esophageal adenocarcinoma.7 This re-
lationship was not observed with CagA-negative
strains. Epidemiologically, this explanation is attrac-
tive, because the rise in BE and esophageal adeno-
carcinoma in many countries correlates with the
decline in H. pylori prevalence.
Finally, we must consider the association between
greater BMI and BE. This has been well docu-
mented among both men and women.8 There is
also a well-documented association between obe-
sity and both symptomatic GERD and esophageal
adenocarcinoma.9 The current “obesity epidemic”
that has affected many nations certainly correlates
with the observed rise in BE. Whether weight loss
can mitigate BE risk has yet to be demonstrated.
In summary, although we do not have data from
randomized trials to definitively demonstrate what
accounts for the rising incidence of BE, there are very
good epidemiological data to support a role for ris-
ing obesity rates and declining H. pylori prevalence.
3. How do different histologic criteria for
Barrett’s mucosa affect the prevalence
rates of BE in different populations? Why




The problem with the definition of BE is that there is
no uniformly accepted definition. There are several;
however, all insist on one of two endoscopic criteria
(region of origin in parentheses):
• Using the lower end of the esophageal palisaded
vessels where no biopsy is necessary (Japan),
although this has to be modified to >5 mm
of palisaded vessels to keep the rate reasonable;
or10
• 1 cm+ from upper end of the gastric folds—less
than this, there is no agreement of where an ir-
regular Z-line stops and short-segment Barrett’s
begins.11
The latter is accompanied by one of three histo-
logical criteria:
(1) No histological criteria—the endoscopic ap-
pearance is quite sufficient—using either of the
two endoscopic criteria stated.
(2) Biopsy of the endoscopically abnormal mucosa
confirmed as showing columnar mucosa of any
subtype (United Kingdom).12
(3) Biopsy with goblet cells (North America and
parts of Europe),13 although this has recently
been modified without any sort of general
education to include all types of glandular
mucosa.14
What effect does this have on prevalence? Clearly,
the change from “must have goblet cells” to “any
columnar lined mucosa” with an appropriate endo-
scopic picture, must result in an increased preva-
lence if these criteria are held strictly. However, it
is impossible to seriously think that in the whole of
North America or much of Europe, one can look
at a length of columnar mucosa in the esophagus
and not believe that it is BE. Nevertheless, as these
patients seem to be at increased risk of getting car-
cinoma,15 this seems justified.
The “Japanese” definition of BE is impossible to
evaluate until a study is carried out that compares
all three potential criteria head to head. Intuitively,
where the Japanese criteria are applied in Europe
or North America, they seem so sensitive, starting
at 5 mm above the gastroesophogeal (GE) junction,
that it seems likely that they would result in an even
greater prevalence of BE. However, there are no data
to suggest that, using these criteria, there is an in-
creased risk of carcinoma, thus the utility of this
definition remains unproven.
The issue of why BE is less common in Asian
countries remains somewhat enigmatic. However,
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it is not just Asia; BE is rare in the Caribbean, the
Middle East, and much of Africa and South America.
If obesity is an issue, then this is not something
on which the West has a monopoly, and while the
overall BMI may be higher in the West, it is sufficient
in other regions for there to be plenty of BE.
The ingestion of a high-fat diet, with its associ-
ated delayed gastric emptying, and possibly oral and
salivary carcinogens that are activated in the region
of the GE junction, may all play a role.16
4. In Barrett’s patients, does the influence
of metabolic changes induced by
adipocytokines and the apparently strong
association existing between obesity,
central adiposity, and BE lead to the need
to reconsider some aspects of the natural
history of BE or only of GERD?
Joel H. Rubenstein
jhr@umich.edu
Epidemiology of obesity and esophageal
adenocarcinoma
It is well documented that the incidence of
esophageal adenocarcinoma has been rising dra-
matically in Westernized countries. Although
genetic factors may predispose individuals to
esophageal adenocarcinoma, the rapid rate of in-
crease in incidence must be due to nongenetic fac-
tors such as behavioral or environmental ones. Dur-
ing the same period of increased incidence of this
cancer, there has been a growing epidemic of obesity
in Westernized countries. Indeed, obesity has been
associated with esophageal adenocarcinoma and BE.
Abdominal obesity is a stronger risk factor than to-
tal body obesity (as measured by BMI) for both BE
and esophageal adenocarcinoma. Furthermore, the
risk of neoplastic progression in BE appears to be
greater in abdominally obese patients.17 There are
at least three potential explanations for these asso-
ciations with obesity (Fig. 1): obesity mechanically
promotes GERD, the relation of obesity with BE
and esophageal adenocarcinoma is confounded by
factors promoting GERD, and obesity promotes BE
and esophageal adenocarcinoma through circulat-
ing adipokines.
Mechanical effect of obesity
A prevalently held hypothesis is that the relation
between obesity and esophageal adenocarcinoma is
due to a mechanical effect of obesity promoting
GERD. Increasing BMI is associated with increased
risk of reporting GERD symptoms.18 Among symp-
tomatic GERD patients, obesity is associated with
more severe esophageal acid exposure.19,20 And
weight loss in patients with GERD is associated
with improvements in symptoms and healing of
erosive esophagitis.21,22 But these findings could be
in part explained by confounding by other factors,
such as diet, discussed below. In a cross-sectional
study of patients undergoing esophageal manom-
etry for clinical indications, obesity was indeed
found to moderately increase intra gastric pres-
sure.23 However, obesity was also associated with
increased intra-esophageal pressure, so the pressure
gradient across the EG junction is less strongly as-
sociated with obesity. For each 10 cm increase in
waist circumference, the pressure gradient across
the EG junction increased only 1.5 mmHg. Abdom-
inal obesity was also weakly associated with hiatal
hernia formation. In addition to the effect of obesity
on the pressure gradient and junctional anatomy, it
is also associated with an increased frequency of
transient lower esophageal sphincter relaxations.24
The combinations of these factors might result in
substantial reflux.
Is the effect of obesity confounded by factors
leading to gastroesophageal reflux?
A number of studies have demonstrated strong asso-
ciations between obesity and BE or adenocarcinoma
Figure 1. Potential roles of obesity and related factors in Barrett’s esophagus.
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including after controlling for GERD symp-
toms,25–27 but there is potential for residual con-
founding in these studies, as subjects may have had
asymptomatic GERD. Furthermore, the apparent
associations could also be confounded by factors
that promote both obesity and GERD, such as diet
and physical inactivity. The Western style diet (high
intake of fat and sweets, low intake of fruits and veg-
etables) promotes obesity, but features of this type of
diet can also directly promote GERD. For instance,
obese patients are more likely to eat chocolate, which
can promote GERD irrespective of any mechanical
effect of their obesity. In fact, in a small study of
obese women with GERD, only 6 days of a very
low carbohydrate diet improved GERD, suggesting
that the baseline diet itself and not obesity, was in-
ducing their symptoms.28 Although some forms of
vigorous physical activity may promote GERD, reg-
ular moderate exercise is inversely associated with
GERD symptoms, controlling for obesity and di-
etary intake, but the mechanism for this association
is not clear.29–32
Potential role of adipokines
Although GERD almost certainly explains at least
part of the relation between obesity and BE and
esophageal adenocarcinoma, it is unlikely to be the
entire explanation. Most patients with GERD symp-
toms do not have erosive esophagitis, and only a very
small minority develop BE. Obesity may play a role
in promoting BE and esophageal adenocarcinoma
in the setting of GERD. Obesity is associated with a
number of other cancers (colon, breast, prostate) for
which there is no known mechanical explanation.
Adipose tissue is not an inert storage depot, but
rather metabolically active, secreting a number of
substances termed adipokines (or adipocytokines)
that can act from a distance through the circula-
tion, promoting inflammation, insulin resistance,
and regulating dietary intake. Visceral adipose tis-
sue appears to be particularly important in these
roles. For instance, visceral adipocytes secrete TNF-
, and 50 to 75% of circulating IL-6 in obese subjects
may be secreted from omental adipocytes.33,34 Alter-
ations in circulating levels of a number of adipokines
have been associated with the development of
other cancers: breast, colon, endometrial, pancreas,
and prostate.35–38 Visceral adipose tissue appears
to mediate the effects of obesity on the risk of
BE.39
Conclusion
BE and esophageal adenocarcinoma are strongly as-
sociated with obesity (Fig. 1). Obesity likely pro-
motes both symptomatic and asymptomatic GERD
through mechanical effects, and obese individuals
are likely to behave in ways that also promote GERD.
In addition, adipose tissue is metabolically active,
and secreted adipokines have been associated with
the development of a number of cancers. The rapid
rise in incidence in esophageal adenocarcinoma may
be due to synergies between these multiple mecha-
nisms of obesity promoting the cancer. Additional
research is needed to elucidate the mechanisms by
which adipokines might promote intestinal meta-
plasia and neoplastic progression.
5. Can it be assessed that the absence of
H. pylori increases the risk of GERD and,
hence, the risk of Barrett’s?
Hala El-Zimaity
Hala.el-Zimaity@uhn.on.ca
Chronic GERD is the strongest risk factor associ-
ated with Barrett’s. Up to 5% of people with long-
standing GERD will develop long segment BE, and
between 10% and 15% will develop short segment
BE. The extent and duration of esophageal acid ex-
posure determines the length of Barrett’s mucosa.
The question is, “can it be assessed that the ab-
sence of H. pylori increases the risk of GERD and,
therefore, the risk of Barrett’s?” The answer to that
question seems controversial. Some data suggests H.
pylori eradication increases the risk of GERD. Other
data suggests the opposite. To understand the op-
posing viewpoints one has to understand the effects
of H. pylori infection on gastric acid secretion.
The associated injury associated with H. py-
lori gastritis begins at the antrum–corpus junction,
specifically at the incisura angularis, with resulting
spread of foci up and down the lesser curvature and
the anterior and posterior wall. A person’s acid secre-
tory status affects both the distribution and severity
of H. pylori related gastritis (for review, see Ref. 40).
In the early stages, H. pylori-associated gastritis is
antral predominant and oxyntic mucosa acid secre-
tion shows an exaggerated gastrin response to H.
pylori, an increase enough to cause duodenal ulcer
disease in some patients. In this setting, H. pylori
eradication decreases acid production.41,42
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With continued inflammation, hypochlorhydria,
and achlorhydria develops, which facilitates proxi-
mal migration of the bacteria. This allows the devel-
opment of corpus gastritis, and eventually corpus
atrophy. Advanced gastritis (patients with gastric
ulcer and the intestinal type gastric cancer) is typ-
ically an extensive pan-gastritis (with widespread
intestinal metaplasia and hypo or achlorhydria).
At this stage, H. pylori eradication increases acid
secretion.43 At this stage, H. pylori eradication per-
haps increases a patient’s risk for GERD.
Meta-analysis shows no association between H.
pylori eradication and the development of new cases
of GERD in dyspeptic patients. However, H. pylori
eradication in cohort studies show a twofold higher
risk for developing erosive GERD in patients with
peptic ulcer disease, OR 2.04 (95% CI: 1.08–3.85;
P = 0.03).44
The natural history of H. pylori gastritis is for the
inflammation to progress from the antrum into the
adjacent corpus. The advancing atrophic front of
corpus injury incrementally destroys parietal cells
causing further reduction in acid secretion with the
eventual development of extensive corpus atrophy.
The extent and severity of gastric atrophy, in par-
ticular corpus atrophy, determines the patient’s risk
for GERD following H. pylori eradication.
6. Are patients with BE hyposensitive to
acid? And what do sensory abnormalities
play in the pathogenesis?
Anne Lund Krarup, Jens Brøndum Frøkjaer,
Christian Lottrup, and Asbjørn Mohr Drewes
drewes@smi.auc.dk
To answer if patients with BE are hyposensitive to
acid, it is first necessary to decide who to compare
with and how the test should be done. To deter-
mine if BE patients are hyposensitive, they should
be compared to healthy subjects. This is often not
done; instead, BE patients are compared to other
patients with reflux disease. When testing, acid sen-
sitivity can be addressed directly by examining the
response to an experimental acid perfusion, for ex-
ample, a Bernstein or modified Bernstein test. Indi-
rect evidence can come from pH and impedance
studies where the number of refluxes sensed by
healthy and patient groups are counted, and the
effects of proton pump inhibitor (PPI) treatment to
complete symptom control can be assessed. Finally,
the Kalixandra study is a unique source of indirect
evidence.
Direct evidence: experimental acid perfusion
In the many studies addressing this issue, patients
with BE have mostly been compared to patients
with erosive reflux disease (ERD) and not healthy
volunteers.
Several studies have demonstrated an acid hy-
posensitivity in patients with BE when compared to
patients with ERD.45 However, patients with ERD
are known to be hypersensitive to acid as well, and
comparisons between ERD and BE can therefore
not tell us anything of BE versus healthy. The com-
parison of patients with BE to healthy age and sex
matched volunteers has only been examined in stud-
ies with fewer than 10 subjects in one of the groups,
and the results are conflicting.46,47 As of now, we
do not have sufficient evidence from direct studies
of acid sensitivity to conclude if patients with BE
are more or less acid sensitive in comparison with
healthy controls.
Until experimental acid perfusion studies on a
larger patient sample with matching healthy con-
trols are conducted, it is not known if BE patients
are truly hyposensitive to acid or only hyposensitive
if compared to ERD patients (Fig. 2).
Indirect evidence
Many studies have demonstrated that patients with
BE have excessive pathological reflux and that these
patients sense fewer reflux events than patients with
ERD.48 Treatment studies in patients with BE have
also proven pathological percentage of time with pH
below 4 despite complete symptom relief from treat-
ment with PPIs. The third piece of indirect evidence
that BE patients are acid hyposensitive came from
the Kalixandra study, which found that only 40%
of patients with BE reported reflux symptoms at all,
but also indicates that only 37% of ERD patients
reported symptoms.3
All of these pieces of evidence could point in the
direction that patients with BE are hyposensitive to
acid, but they are still indirect evidence.
Conclusion
Indirect and direct evidence exists of acid hyposensi-
tivity in patients with BE compared to other groups
of reflux patients. However, in comparison with
healthy individuals the direct evidence is sparse, and
results are conflicting. Not until BE patients have
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Figure 2. Several studies have demonstrated acid hyposensitivity in patients with BE when compared with ERD. However, in
comparisons of BE patients with healthy volunteers, there have only been studies with fewer than 10 subjects in one of the groups,
and the results are conflicting. As of now, we do not have sufficient evidence to conclude if patients with BE are more or less acid
sensitive in comparison with healthy controls.
been compared to healthy subjects in experimen-
tal studies, where the nature of the acid stimulus is
controlled (area, volume, and composition of the
acid stimulus) can it be shown if patients with BE
patients are truly acid hyposensitive.
7. What can we tell about the etiology of
BE from experimental testing of the
esophagus with multimodal sensory
assessment?
Asbjørn Mohr Drewes, Anne Lund Krarup,
Christian Lottrup, and Jens Brøndum Frøkjær
amd@mech-sense.com
Assessment of visceral pain
Basic mechanisms in pain processing can be ex-
plored by means of human experimental pain
models. These models, when applied to healthy
volunteers or to patients, provide an important
translational link between animal studies and hu-
man clinical trials. In clear contrast to clinical pain,
experimental pain models allow the possibility of
controlling the duration, the intensity and the na-
ture of the pain stimulus. However, as pain is a mul-
tidimensional perception it is obvious that the reac-
tion to a single stimulus of a certain modality only
represents a limited part of the pain experience and,
therefore, a variety of stimulus modalities are re-
quired.49 This was the rational for development of
the multimodal pain model for the esophagus.50
The main advantage of the model is that it allows
a differentiated assessment of the superficial and
deep structures of the gut wall, activation of dif-
ferent receptors, nerve fibers and peripheral as well
as central pain mechanisms. The model has been
proved to be robust and reliable across experimental
sessions. The validity of the model was confirmed
in a series of studies where it was used to explore
the pathophysiology of esophageal disorders such as
erosive and nonerosive reflux disease and noncar-
diac chest pain. Recently, the model was also used to
investigate the sensory system in patients with BE51
(Fig. 3).
Sensory abnormalities in BE
Several studies have confirmed that patients with
BE have pathologic gastroesophageal reflux and slow
clearance of acid and other noxious substances from
the esophagus. This may be a main factor in the
pathogenesis. The reduced clearance could be re-
lated to a defect in the afferent (sensory) or efferent
(motor) part of the reflex arc leading to fewer sec-
ondary contractions. Previous studies have shown
Figure 3. The probe used for multimodal stimulation of the
esophagus. The probe allows controlled mechanical, thermal
(circulation of heat and cold water with simultaneous measure-
ment of temperature), and electrical stimulation. Furthermore,
hyperalgesia of the esophageal mucosa can be evoked with acid
(not used in the BE experiment).
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that patients with BE have decreased sensation to
acid and mechanical stimulation of the esophagus,
and, hence, the reduced clearance could be related to
a generalized defect in the afferent nerves.52,53 It is
not yet known whether this change in esophageal
sensation is a result of the characteristics in the
metaplastic mucosa or whether it is present be-
fore development of the metaplasia. We hypothe-
sized that patients with BE had primary defects in
the afferent signaling (thus leading to reduced acid
clearance).
To explore this in detail, we subjected 15 patients
and 15 volunteers to mechanical, heat, and electri-
cal stimulation of the metaplastic and normal parts
of the esophagus. We found that patients with BE
were hyposensitive to heat and partly to mechanical
stimulation both in the metaplastic and normal part
of esophagus. As the hyposensitivity was present on
both segments it was suggested that patients with BE
may have a generalized sensory defect in the esoph-
agus independent of nervous changes related to the
metaplastic mucosa. Hence, the hyposensitivity is a
cardinal feature that may bias the clinical evaluation
and monitoring of patients with BE, and may be one
of several pathogenetic factors in BE to be studied
in more detail.
8. Does BE really develop in adulthood?
Katie S. Roark, Stephen J. Sontag, Thomas G.
Schnell, Jack Leya, and Gregorio Chejfec
kroark@lumc.edu
The incidence of BE is increasing. In clinical prac-
tice, the true definition of incident Barrett’s is the
number of patients which actually “develop” Bar-
rett’s during a specific time. There have been many
speculations as to the reason for the rising incidence.
Per review of the current literature, nothing has ever
been published regarding when and how long be-
fore people go on to actually “develop” BE, which
would define the true incidence of this disease.
When BE is diagnosed, did it just recently occur or
had it been there for a while but was just recently dis-
covered? Based on an observation that the majority
of BE is diagnosed on initial endoscopy and a clini-
cal question of “when does BE actually develop,” we
set out to determine the true incidencehood of BE.
To find true incidence of this disease, one must
observe the replacement of Squam epithelium (Ep-
ith) by intestinal metaplasia (IM). Our data proves
that during our 25-year surveillance program for
GERD, only 4.6% of patients actually develop BE
after a negative evaluation for Barrett’s. The other
87% are actually prevalent Barrett’s cases or BE di-
agnosed on first endoscopy. This makes the true
incidence of BE almost negligible after initial nor-
mal endoscopy. It raises discussion that Barrett’s is
most likely present at a much younger age than when
initially diagnosed.
The methods we used include our Hines VA GI
Database, which contains the data of all proce-
dures performed since January 1979. EGDs were
performed by one of three endoscopists (TS, SJS,
JL) using the same criteria and definitions. EGD
retroflexion was routinely performed to assess the
GEJ. Specimens (specs) were taken from all poten-
tial BE segments. In general, a minimum of two
Bx specs were routinely taken from the SCJ regard-
less of a “normal” appearance. Histology specs were
read by one pathologist (GC). An absolute crite-
rion for BE was intestinal metaplasia (IM) from the
tubular esophagus, the Bx had to contain (as one
specimen) the squamo-IM junction. To qualify for
“Incidence BE,” junctional epithelium (J) from the
SC junction had to be present on previous Bx at
least 12 months before the diagnosis of IM (BE;
Fig. 4).
We found that since 1979 1,648 patients (mean
age 58 years at first EGD) have been diagnosed to
have BE and followed in outpatient surveillance pro-
gram. Of the 1648 patients, 209 had Barrett’s diag-
nosed 12 months after initial endoscopy. We per-
formed a detailed review of the individual scope
report, photos, and diagrams of these patients and
found that 53 had squamous (Sq) on initial scope, 79
had no biopsy during their first endoscopy, and 77
(4.6%) had actual junctional epithelium preceding
the IM.
We conclude from the data that in our database
of 25 years (mean 15.2 years) the documented inci-
dence of BE is at best 0.83% per year, indicating that
>99% of BE develops before initial endoscopy.
So, when does BE develop? Depending on the true
prevalence and incidence of BE in children, BE in
adults may possibly be congenital—an abnormality
of incomplete embryogenesis perhaps related to the
cervical inlet patch.54 One thing is for certain, based
on our data, Barrett’s most likely develops before we
look!
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Figure 4.
9. What is the role of duodeno-




There is now overwhelming evidence supporting the
association of GERD and BE. However, the role of
individual constituents of the gastric reflux in the
development of BE and its associated complications
still remain uncertain. Gastric acid and pepsin have
received the most attention; however, the develop-
ment of BE in a few achlorhydric or postgastrectomy
patients suggests a possible role for the duodenal
contents. The duodenal contents suspected of caus-
ing esophageal mucosa injury include bile acids and
lysolecithin present in the bile secretions as well as
the pancreatic enzymes trypsin.
Although commonly referred to as “bile re-
flux,” it is important to remember that reflux of
duodenal contents contain more than just bile.
Furthermore, the term “alkaline reflux” is often
used interchangeably suggesting that pH 7.0 rep-
resents the reflux of duodenal contents into the
lower esophagus. However, recent studies have con-
firmed the inadequacy of pH monitoring under
these circumstances.55 Therefore, duodeno-gastro-
esophageal reflux (DGER) is a more appropriate
term representing the retrograde reflux of duodenal
contents into the stomach with subsequent reflux
into the esophagus. The best methodology for mea-
suring DGER has been the Bilitec monitoring system
developed in the early 1980s. This is an ambulatory,
fiber optic probe that uses the optical property of
bilirubin, the most common pigment found in bile,
to detect DGER spectrophotometrically, indepen-
dent of pH.
Using combined 24 pH and Bilitec monitoring,
studies of patients with and without complications
of BE have found increased reflux of bile and acid
into the lower esophagus of both groups as com-
pared to controls.55,56 Esophageal exposure to both
acid and DGER was the most prevalent pattern
(Fig. 5) and present in 100% of complicated Barrett’s
patients, 89% of uncomplicated Barrett’s patients,
79% of patients with esophagitis, and 50% of pa-
tients with NERD. Furthermore, subsequent studies
found that simultaneous esophageal acid exposure
to both acid and DGER was the most prevalent re-
flux pattern, occurring in 95% of patients with BE
and 79% of GERD patients.56 In fact, these authors
found a strong correlation (R = 0.73) between acid
and DGER in controls, reflux patients, and those
with BE. Thus, these studies in humans confirm that
a synergy exists between acid and DGER, which may
contribute to the development of esophagitis and
possibly BE.
This was confirmed in a cohort of 392 patients
with GERD, where a multivariate analysis found
that the presence of a hiatal hernia, increasing body
mass index, and GER were important risk factors for
the recurrence of esophagitis, but acid exposure was
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Figure 5. Esophageal exposure to both acid and DGER was the most prevalent pattern and present in 100% of complicated
Barrett’s patients, 89% of uncomplicated Barrett’s patients, 79% of patients with esophagitis, and 50% of patients with NERD.
the principle factor in determining the severity of
esophagitis. Similarly, the DGER and acid synergy
is important in the development of BE and its com-
plications. Multivariate analysis of two large cohort
of patients with DGER identified male gender and
exposure to both acid and DGER as important risk
factors for BE.57–59
10. What is the role of acute and chronic
bile acid exposure in reflux induced
oxidative stress?
Gareth Jenkins, E. McAdam, N. Rawat, L. Williams,
J. Cronin, Z. Eltahir, P. and Griffith, J. Baxter
g.j.jenkins@swansea.ac.uk
Oxidative stress is said to occur when the levels of
ROS present in a tissue outweigh the inherent an-
tioxidant defenses, that is dietary antioxidants (vita-
min C, etc.) and antioxidant enzymes (glutathione
S transferase, superoxide dismutase (SOD), etc.).
ROS induced during times of oxidative stress have
been implicated in a wide range of diseases such
as diabetes, aging, degenerative inflammatory con-
ditions, and of course cancer. In terms of cancer,
ROS are known to induce redox sensitive signal-
ing pathways, DNA and chromosome mutations
and damage to other macromolecules (proteins,
lipids, etc.). These cellular/DNA effects contribute
to the neoplastic development of a tissue by in-
creasing cell division rates and introducing genomic
instability.
In the premalignant condition BE, oxidative stress
has been strongly linked to disease progression
(Wetscher et al.60 Dvorak et al.61). This oxidative
stress has been shown to be induced in epithelial cells
by exposure of these cells to both bile acid (Jenkins
et al.64) and acid (Zhang et al.74) components of
refluxate. Oxidative stress can also be induced in
esophageal tissues by:
1. ROS produced by infiltrating neutrophils dur-
ing acute inflammatory phases;
2. reductions in antioxidant enzyme levels (GSH,
SOD) known to be apparent in Barrett’s tissues;
and
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3. reduced dietary antioxidant levels in the serum
of Barrett’s patients.
These latter two observations may be due to in-
creased levels of ROS in Barrett’s tissues leading to
antioxidant depletion. Nonetheless, this state of af-
fairs means that ROS are key players in neoplas-
tic progression in esophageal adenocarcinoma in
particular.
Because of the fact that ROS are clearly im-
plicated in BE progression, it would make some
sense (and provide some additional evidence) if
dietary antioxidant intake protected patients from
cancer progression. This is indeed the case, with
several patient studies showing an inverse associ-
ation between dietary intakes of antioxidants and
risk of progressing from BE to adenocarcinoma.
There is, however, some controversy as to whether
dietary antioxidants or antioxidant supplements
are the best source of protection. A recent meta-
analysis of published studies shows odds ratios of
0.49 for high intakes of dietary vitamin C and
0.46 for high intakes of dietary beta-carotene.64
Hence, a greater than 50% reduced risk of cancer
for those Barrett’s patients with high intakes of an-
tioxidants, this clearly supports the hypothesis that
oxidative stress drives cancer progression in these
patients.
However, there has been limited success in
chemoprevention studies in both animal models
and Barrett’s patients, where surrogate markers of
disease progression have been studied (White et al.65
and Murphy et al.66). A recent study highlighted the
potential effect of patient heterogeneity on the suc-
cess of such intervention studies. In a small vitamin
C supplement study (1 g/day for 31 days) involving
25 patients, Babar et al.67 looked at NF-B activity
and cytokine expression levels as surrogate markers
in patient tissues, both before and after supplemen-
tation. They found that overall there was little effect
of supplementation on average levels of NF-B ac-
tivity and cytokine expression. However, when look-
ing at individual patients, they noted that within
these 25 patients, 8 patients (35%) showed suppres-
sion of the markers studied after supplementation,
whereas the other patients showed little effects. This
perhaps highlights the potential for heterogeneity
between these patients to affect the overall results of
the study.
For example, for patients who already have high
intakes of dietary antioxidants, supplementation
with vitamin C will have little effect, whilst for those
with low initial intakes, the supplementation may
show strong effects. Therefore, in short-term stud-
ies, it is always going to be difficult to show a strong
effect of supplementation, unless this patient het-
erogeneity is taken into account. Indeed, patient
stratification may be desirable in such studies, as
would be longer-term supplementation, where at
all possible.
In conclusion, there is strong evidence that oxida-
tive stress drives neoplastic development in Barrett’s
tissues. Dietary antioxidant levels appear to prevent
neoplastic development and hence support the con-
cept that ROS are crucial carcinogens in these pa-
tients. However, there are still gaps in our knowledge
which need to be filled if we are to better under-
stand the mechanisms involved in neoplastic devel-
opment, including the source of these ROS in the
esophagus, which is still unclear. Indeed the relative
contributions of acid and bile to the generation of
these ROS, along with the pathways/enzymes lead-
ing to these ROS and even the different types of ROS
induced, require further study.
11. What is the current understanding of
the role of DNA damage induced by bile
acids in the development of BE?
Aaron Goldman and Katerina Dvorak
kdvorak@email.arizona.edu
DNA damage is one of the most detrimental effects
of exposure to toxic, caustic, and harmful agents.
The mechanisms underlying DNA repair are imper-
fect procedures and the pathological consequences
of poor repair processes have been well documented
in familial and acquired diseases. Although toxic
chemicals from exogenous sources have the ability
to produce immense DNA damage within tissue,
endogenous chemicals can find their way from the
constraints of their normal physiological environ-
ment to damage neighboring tissue. The latter case
is specifically associated with the development of
BE.
BE is a premalignant condition arising in the dis-
tal esophagus. It is a condition where metaplastic
tissue resembling the columnar epithelium of the
intestines, containing goblet cells, replaces normal
mucosa. Clinical, animal, and basic studies suggest
that BE develops as the consequence of chronic ex-
posure of stomach contents, mainly acid and bile
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acids, on the squamous epithelium. These endoge-
nous components individually elicit a series of mali-
cious events and together are synergistic within the
esophagus, most notably resulting in DNA damage.
Acid alone has the ability to hydrolyze nucleic acid
bases causing the liberation of purines and pyrim-
idines from the sugar backbones on which they re-
side. This depurination or depyrimidation requires
the imperfect process of base excision repair to re-
solve the missing base within the DNA sequence.
As a consequence, incorrectly placed bases can re-
sult in the activation of oncogenes, loss of tumor
suppressors and onset of pathology.
Bile acids have previously been shown to increase
nitric oxide synthase expression and nitric oxide
production, generate superoxide radicals via acti-
vation of NADPH oxidase (NOX) and perturb the
mitochondrial membrane.68 These responses elicit
large amounts of reactive oxygen species (ROS) and
reactive nitrogen species (RNS), consequently in-
ducing DNA damage in squamous and BE cells.69
When bile acids are combined with acid, mimicking
the reflux experienced by patients who have BE, the
DNA damage elicited by each component of reflux
becomes synergistic and results in amplified DNA
damage.70,71 Squamous epithelium is less protected
and ill-prepared to manage the onslaught of DNA
damage associated with chronic exposure to bile
acids and acid.
Squamous cells do not retain sufficient defense
mechanisms to ward off ROS, increased extracel-
lular acidity and activation of oncogenic pathways
as a result of the synergism elicited by bile acids
and acid. Following acute exposures of <10 min-
utes to bile acids and acid, squamous cells evoke
increased DNA damage. As DNA repair takes place,
there is likelihood for inefficient repair and mu-
tations can occur. Moreover, in response to DNA
damage as a consequence to increased acidity, cells
will adapt mechanisms to defend from the insult,
developing new cells from progenitor cells that are
better adapted to refluxate environment. BE tissue
is able to more effectively defend against bile acids
and acid exposure.
BE tissue is adapted to an environment contain-
ing bile acids and gastric acid. First, mucin secreted
by goblet cells provides a protective layer of mu-
cous. Second, BE cells display increased expression
of proteins associated with acid removal required
for modulation of the extracellular and intracellu-
Figure 6. Proposed scheme of bile acid and acid-mediated
DNA damage. Bile acids enter the cell or are transported in
by ASBT, where they liberate ROS from the mitochondria or
through activation of NOX. Activation of NOS leads to inhi-
bition of NHE, increased acidity, and NO-mediated and acid-
mediated DNA damage. ASBT, apical sodium-dependent bile
acid transporter; BA, bile acid; NOX, NADPH oxidase. Adapted
from Ref. 68.
lar acidity, such as Na+/H+ exchanger.70,71 These
cells still incur a sufficient amount of DNA dam-
age in response to acid and bile acids, but through
their development of acid extrusion pathways such
as Na+/H+ exchanger, they are able to resist cell
death to a greater degree than squamous derived
cells under the same conditions.63,70
The progression of squamous epithelium in the
esophagus to BE metaplasia is a multifaceted pro-
cess. One of the culprits which elicit a response
by the cell to develop defense mechanisms is
the DNA damage incurred by bile acid–associated
ROS, NO, and acid-mediated increases in ROS
(Fig. 6). These mechanisms of damage become
synergistic when bile acids are combined with acid.
DNA damage becomes more pronounced and the
cells are forced to adapt, incur mutations, and
progress through Barrett’s to cancer.




The pathophysiology of GERD is complex, and in-
volves diverse factors, that is, gastric acid secre-
tion, dysfunction of the antireflux barrier, delayed
gastric emptying, and abnormalities in esophageal
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defence mechanisms. How these different factors
cause GERD is not well understood, however, they
all share one common initiating event: the increased
exposure of the esophageal squamous epithelium to
gastric contents.
It is generally agreed that gastric content, which
consists of acids, pepsin, trypsin, and bile salts,
causes caustic and chemical mucosal injury. This
process starts at the luminal surface and progresses
through the epithelium into the submucosa. Indeed,
pepsin breaks junctional proteins and, as a con-
sequence, increases mucosal permeability, thereby
making it possible for hydrogen ions and bile to
enter the submucosal layer. However, this process
results in different outcomes. Indeed, about 60% of
patients develop nonerosive esophagitis, 35% ero-
sive esophagitis, and finally about 5% of patients
develop complicated esophagitis called “Barrett’s
esophagus” and adenocarcinoma.
The degree of esophageal mucosa damage does
not correlate with the amount of reflux materials
and, to date, the exact pathogenetic mechanisms
responsible for the diversity of esophageal pheno-
types are poorly understood. Although there is a
large body of data focusing on damage of the epithe-
lial layer in response to acid, little is known about
the molecular events underlying the development
of esophageal inflammation.
One of the key steps of the pathogenetic pro-
cess of GERD is the recruitment and activa-
tion of polymorphnuclear cells that, in turn, re-
lease ROS and nitric oxide that cause esophageal
mucosal damage. Therefore, microbes are among
the environmental factors that may contribute to
the etiology of GERD. In a recent study of mi-
crobiomes from biopsy esophageal samples, Yang
et al.72 found that the esophageal microbiome is
prevalently constituted by bacteria of the streptococ-
cus genus in normal subjects, and by gram-negative
anaerobe/microaerophile bacteria in patients with
esophagitis and BE.
Another interesting concept concerns the im-
mune response underlying the esophageal mucosal
damage. The esophageal epithelium is embryolog-
ically, morphologically, and functionally related to
the skin epithelium, which is recognized as a ma-
jor immunological organ. Therefore, we can con-
sider the esophagus an immunological organ. The
reflux of gastric content in the esophagus may
activate T cells in the submucosal layer that, in
turn, release cytokines and chemokines. Cytokine
and chemokine agents, through the recruitment of
Figure 7. An alternative concept for the development of reflux esophagitis. The reflux of gastric juices does not directly damage
the esophagus, but rather stimulates esophageal epithelial cells to secrete chemokines that, in turn, through the recruitment of
neutrophils and the release of nitric oxide (NO) and reactive oxygen species (ROS), mediate the damage of esophageal mucosa.
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polymorphonuclear cells and the release of inflam-
matory mediators, may initiate, amplify, and termi-
nate the mucosal damage.73
Therefore, esophageal damage starts in the sub-
mucosal layer and depends prevalently on cytokine
secretion (Fig. 7). Indeed, in a rat model of re-
flux esophagitis, the inflammatory infiltration oc-
curs early and appears to be prevalently restricted
to the submucosal layer; in contrast, mucosal alter-
ations, that is, basal cell proliferation and papillary
cell hyperplasia, occur after two weeks.73
From a molecular viewpoint, the reflux of gas-
tric contents in the esophagus activates membrane
protease activated receptor 2 that in turn induces
phosphorylation of IB and its subsequent degra-
dation. This results in activation of NF-B and its
translocation into the nucleus. At this point, NF-B,
which is involved in various inflammatory condi-
tions through a plethora of genes, upregulates the
transcription of IL-8, thereby inducing strong re-
cruitment of neutrophils.74
A progressive significant molecular increase of
p65 and p50 subunits of NF-B has been detected
in patients with esophagitis and BE. Moreover, IL-8
mRNA expression and mucosal neutrophil infiltra-
tion have been reported to be significantly related to
the endoscopic severity of reflux esophagitis scored
according to the Los Angeles classification.74 Finally,
the mucosal levels of IL-8 were found to be indica-
tive of esophagitis relapse. Taken together these ob-
servations suggest that IL-8 is a sensitive marker of
esophageal mucosal damage.
A large number of cytokines may be involved
in esophageal mucosal injury, for example, IL-1,
IL-6, and IL-10, that may affect motility function,
fibrosis, cell immune response, and carcinogene-
sis.75 In the case of eosinophilic esophagitis, the
regulation of the inflammatory-immune response
is even more complex and involves IL-5, IL-13,
eotaxin, and fibroblast growth factor, which affect
muscle cells and fibroblast and may induce motil-
ity dysfunction and fibrosis. The cytokine profile
may explain the different findings and outcomes of
esophageal disease. Fitzgerald et al.76 analyzed biop-
tic samples of esophageal mucosa, and observed that
BE is characterized by a distinct Th2 predominant
cytokine profile, that is, IL-4 and IL-10, whereas
esophagitis is characterized by a proinflammatory
cytokine profile consisting of IL-8, IL-1, IL-6, and
IFN- .76
Therefore, by stimulating submucosal T cells, the
reflux of gastric content, as well as environmental
agents such as bacteria and food allergens, may in-
duce secretion of cytokines, chemokines, and related
inflammatory mediators that can affect fibroblasts,
immune cells, muscle cells, and endothelial cells.78,79
If the inflammatory reaction persists, motility dis-
orders, fibrosis, and even cancer may occur. These
recent data are consistent with an alternative concept
for the development of reflux esophagitis in which
the reflux of gastric juices does not directly dam-
age the esophagus, but rather stimulates esophageal
epithelial cells to secrete chemokines that, in turn,
mediate the damage of esophageal mucosa.
In conclusion, GERD may be considered an
immune-mediated disease starting at the submu-
cosal layer and the cytokine profile of the mu-
cosal immune response may explain the different
outcome of gastresophageal reflux, the severity of
mucosal injury and even the relapse of esophagi-
tis. Finally, this new concept opens the way to the
development of new treatment for patients who
do not respond to PPIs, and to the prevention of
carcinogenesis.
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